Lodenosine

From Wikipedia, the free encyclopedia
Lodenosine
Names
IUPAC name
[(2S,4S,5R)-5-(6-Amino-9H-purin-9-yl)-4-fluorooxolan-2-yl]methanol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1 checkY
    Key: KBEMFSMODRNJHE-JFWOZONXSA-N checkY
  • InChI=1/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1
    Key: KBEMFSMODRNJHE-JFWOZONXBK
  • F[C@H]3C[C@H](O[C@H]3n2cnc1c(ncnc12)N)CO
Properties
C10H12FN5O2
Molar mass 253.23 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Lodenosine is a failed experimental agent for the treatment of HIV. Its development was discontinued on January 11, 2001.[1]

References[edit]

  1. ^ "Drug Profile: Lodenosine". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 4 December 2015.